A. Immunofluorescence using an a-NUAK1 antibody of the described cell lines. DAPI is used as nuclear counterstain (n=3).
B. Immunofluorescence using an a-HA antibody of U2OS or MCF10A cells expressing HA-tagged NUAK1 (and their empty vector, EV, counterpart). DAPI is used as nuclear counterstain (n=3 A. Specificity control of the proximity ligation assay (PLA) shown in Figure 2B . The assay was performed using only the HA antibody. DAPI is used as nuclear counterstain (n=3 F. GO terms of differentially phosphorylated proteins identified in response to both BAY-880 and HTH-01-015. For each term and each treatment, the ranking, the number of identified hits, the fold enrichment and the false discovery rate (FDR) is reported.
G. Top: Venn diagram of proteins with the phosphosites identified as described in Figure 4D . A. Immunoblot using the indicated antibodies. U2OS MYC-ER cells were incubated with 100 nM 4-OHT for 20 h and treated with 10 µM BAY-880 for the last 4 h. VCL was used as loading control (n=3).
B. Histogram representing the ratio of pre-mRNA reads (defined in Figure 5A ) between 4-OHT treated ("+MYC") and EtOH treated cells ("-MYC") of all genes in the 4sU-labeling experiment.
Samples upon 15 min 4sU incorporation ("pulse", "P") are shown.
C. Blue, browser tracks documenting nascent RNA synthesis at the indicated genes as determined The kinase selectivity screening was performed employing the KinaseProfiler Assay (Eurofins).
%, percentual residual kinase activity upon 1uM BAY-880 treatment. 
